Plumbing the Core and Nibbling at the Margins of Cancer

Cancer Commons Editor in Chief George Lundberg, MD, is the face and curator of this invitation-only column

  •  

    The Promise of Plerixafor in Glioblastoma Treatment

    With: Adan Rios, MD

    A Q&A with Adan Rios, MD; Professor in the Division of Oncology-Department of Internal Medicine of The University of Texas McGovern Medical School at Houston, Texas Medical Center; adan.rios@uth.tmc.edu Q: Glioblastoma multiforme (GBM) remains a scourge with a typically rapid fatal course resistant to most therapy. All solid tumors must receive sufficient blood supply to grow. Plerixafor is an FDA-approved drug that may inhibit… Read more »

  •  

    Who Owns Patient Data in Clinical Research?

    With: Charlotte J. Haug, MD, PhD, MSc

    A Q&A with Charlotte J. Haug, MD, PhD, MSc, International Correspondent, New England Journal of Medicine; Senior Scientist, SINTEF Techology and Society; Adjunct Affiliate, Stanford Health Policy; Oslo, Norway; charlottejohanne@gmail.com Originally published October 25, 2017 Q: Many people are coming to believe that active patient participation will be a key to more rapid movement forward in cancer research. Data sharing can help. But who owns the… Read more »

  •  

    Might Cancer Be a Metabolic Disease?

    With: Thomas N. Seyfried, PhD

    A Q&A with Thomas N. Seyfried, PhD, Professor of Biology, Boston College Q: As a geneticist, you know that the genomic makeup of cancers recently has captivated much of the scientific community with new knowledge and new treatments. And yet, cancer outcomes remain dismal for many patients. You have written about cancer from a very different perspective. Why do you consider cancer to be… Read more »

  •  

    Accuracy and Precision Define Radiation Oncology

    With: Eddy Yang, MD, PhD

    A Q&A with Eddy Yang, MD, PhD, Professor and Vice Chair of Translational Sciences Department of Radiation Oncology; Deputy Director, Associate Director of Precision Oncology at the Hugh Kaul Precision Medicine Institute; Birmingham, AL; shyang@uabmc.edu Originally published December 5, 2017 Q: You are a radiation oncologist with a particular interest in cancer of the prostate. How does the molecular study of prostate, as well… Read more »

  •  

    Options to Treat a Glioblastoma

    With: Al Musella, DPM

    Please see our updated version of this article from Oct 1, 2020. A Q&A with Al Musella, DPM, President, Musella Foundation For Brain Tumor Research & Information, Inc., Hewlett, NY; email: musella@virtualtrials.com, phone: 888-295-4740 Q: You direct an established foundation that supports research and information about brain tumors. What would you do if you yourself were diagnosed with a glioblastoma multiforme (GBM)? A: Now… Read more »

  •  

    Huge Progress in Palliative Care

    With: Diane E. Meier, MD, FACP

    A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY; diane.meier@mssm.edu Originally published November 8, 2017 Q: You wrote in MedGenMed in 2007 that palliative care was the job of all hospitals. In October 2017 you were honored at the National Academy of Medicine for… Read more »

  •  

    Patient-Reported Outcomes Could Transform Cancer Care

    With: Jared Adams MD, PhD

    A Q&A with Jared Adams MD, PhD, Chief Science Officer at Self Care Catalysts; jared@selfcarecatalysts.com Q: Patient-reported outcomes (PROs) are health care outcomes, such as symptoms or quality of life, reported directly by a patient. In recent years, PROs have emerged as a potentially powerful new way to understand cancer outcomes. Could PROs lead to the next breakthrough in our understanding of cancer? A: When biochemist and… Read more »

  •  

    Do You Have Pain, Cancer, or Diabetes? Your PBM May Now Be Your Doctor for These Illnesses.

    With: Charles L. Bennett, MD, PhD, MPP

    A Q&A with Charles L. Bennett, MD, PhD, MPP; Smart State and Frank P and Jose M Fletcher Chair, Medication Safety and Efficacy, Smart State Center of Economic Excellence, University of South Carolina and the Hollings Cancer Center at the Medical University of South Carolina; Charleston, South Carolina; Email: charlesleebennett@gmail.com Originally published December 27, 2017 Q: The opioid epidemic is now a public health… Read more »

  •  

    Why the 21st Century Cures Act is a Good Thing

    With: Mary Woolley

    A Q&A with Mary Woolley, President and CEO of Research!America Q: You attended the December 2016 signing by President Obama of the 21st Century Cures Act and are recognized to be a strong supporter. Yet harsh criticism of it has quickly appeared in JAMA, BMJ, a variety of other venues, as well as on these pages. Please tell our readers why this is good legislation… Read more »

  •  

    Q&A: Air Traffic Control for Cancer

    With: David K. Cundiff, MDJeff Shrager, PhD

    A Q&A with David K. Cundiff, MD, Retired internist and palliative care physician from LA County + USC Medical Center; Email: dkcundiff@whistleblowerdoctor.org. Jeff Shrager, PhD, Director of Research, Cancer Commons; Adjunct Professor, Symbolic Systems Program, Stanford University; Email: jshrager@gmail.com. Originally published August 16, 2017 Q: After May 17, 2017, you and Jeff Shrager engaged in a robust discussion about the place, if any, for an “Air… Read more »